The Hib conjugate vaccine induces T-cell dependent immunity by linking PRP to a carrier protein, offering effective protection against invasive diseases. India's inclusion of Hib in its pentavalent formulation has led to measurable declines in meningitis and pneumonia cases, confirming the vaccine’s immunological and epidemiological impact.